Cooperative Agreement AID176A1400002

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $492,980 to the University of Virginia (UVA) to investigate how variations in the HIV Rev-Rev Response Element (Rev-RRE) regulatory system impact viral transmission and latency. The project aims to define the role of Rev-RRE variation in sexual transmission, explore the contribution of the Rev-RRE axis to latency...

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...

This Project Grant award of $769,471 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the "HIV Enhanced Access Testing in Emergency Department Program Using a Systems Analysis and Improvement Approach (HEATED-SAIA) Cluster Randomized Trial". The program aims to enhance delivery of HIV testing services (HTS) in emergency departments (EDs) in Kenya, targeting hard-to-reach populations like men, adolescents,...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,554,273 to the Fred Hutchinson Cancer Center in Seattle, WA to assess the impact of oral pre-exposure prophylaxis (PrEP) on the pharmacokinetics of monoclonal antibodies and vaccine-induced antibodies among women vulnerable to HIV-1. The key objectives of this 4-year award are to: 1) Determine whether oral...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) provides $812,427 to the University of California, San Diego (UCSD) to develop an interactive online data dashboard. The dashboard will integrate de-identified and aggregated HIV sequence data with publicly available Ending the HIV Epidemic (EHE) prevention and treatment data to identify regions with heightened HIV...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...

This $536,943.46 Project Grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases funds research at The Scripps Research Institute-Florida on identifying host factors that regulate HIV latency and reactivation. The grant supports three aims over a six-month period: defining the roles of proteins P32, FUBP3, and PHB2 in HIV transcription and chromatin structure; investigating protein complexes associated with P32, FUBP3, and PHB2 and their interaction...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,016,951 to The University of Texas MD Anderson Cancer Center to conduct research on reversing the immune system changes that lead to the establishment of the HIV reservoir during antiretroviral therapy (ART) initiation. The goal is to use TGF-beta blockade, combined with broadly neutralizing...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $617,376 to Emory University to conduct research on the activation and maturation of the HIV-1 virus. The key objectives are to: 1) Measure the timing of protease (PR) activation relative to HIV-1 budding from the host cell, 2) Assess the rate and extent of PR substrate cleavage and correlate this with formation of...